These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 38359731)
1. Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis. Peixoto JF; Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Finkelstein LC; Dias-Lopes G; Patricio BFC; Lima CGS; Rocha HVA; da Silva FC; Ferreira VF; Pereira BAS; Alves CR Int J Parasitol Drugs Drug Resist; 2024 Apr; 24():100525. PubMed ID: 38359731 [TBL] [Abstract][Full Text] [Related]
2. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis. Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693 [TBL] [Abstract][Full Text] [Related]
3. Development of a microemulsion loaded with epoxy-α-lapachone against Leishmania (Leishmania) amazonensis murine infection. Peixoto JF; Gonçalves-Oliveira LF; Souza-Silva F; Côrtes LMC; Dias-Lopes G; Cardoso FO; Santos RO; Patricio BFC; Nicoletti CD; Lima CGS; Calabrese KDS; Moreira DL; Rocha HVA; da Silva FC; Ferreira VF; Alves CR Int J Pharm; 2023 Apr; 636():122864. PubMed ID: 36934883 [TBL] [Abstract][Full Text] [Related]
4. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525 [TBL] [Abstract][Full Text] [Related]
5. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate. Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977 [TBL] [Abstract][Full Text] [Related]
6. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment. Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239 [TBL] [Abstract][Full Text] [Related]
7. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis. Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857 [TBL] [Abstract][Full Text] [Related]
8. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum. Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726 [TBL] [Abstract][Full Text] [Related]
9. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice. Moosavian SA; Fallah M; Jaafari MR Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544 [TBL] [Abstract][Full Text] [Related]
10. Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment. Pivotto AP; de Souza Lima LB; Michelon A; Ferreira CZP; Gandra RF; Ayala TS; Menolli RA Med Microbiol Immunol; 2024 Mar; 213(1):4. PubMed ID: 38532203 [TBL] [Abstract][Full Text] [Related]
11. Antileishmanial activity of 1,3,4-thiadiazolium-2-aminide in mice infected with Leishmania amazonensis. Rodrigues RF; Charret KS; da Silva EF; Echevarria A; Amaral VF; Leon LL; Canto-Cavalheiro MM Antimicrob Agents Chemother; 2009 Feb; 53(2):839-42. PubMed ID: 19015338 [TBL] [Abstract][Full Text] [Related]
12. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850 [TBL] [Abstract][Full Text] [Related]
13. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice. Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416 [TBL] [Abstract][Full Text] [Related]
14. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report. Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747 [TBL] [Abstract][Full Text] [Related]
15. Epoxy-α-lapachone has in vitro and in vivo anti-leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite. Souza-Silva F; Bourguignon SC; Pereira BA; Côrtes LM; de Oliveira LF; Henriques-Pons A; Finkelstein LC; Ferreira VF; Carneiro PF; de Pinho RT; Caffarena ER; Alves CR Antimicrob Agents Chemother; 2015 Apr; 59(4):1910-8. PubMed ID: 25583728 [TBL] [Abstract][Full Text] [Related]
16. Effect of natural naphthoquinones in BALB/c mice infected with Leishmania amazonensis and L. venezuelensis. Fournet A; Barrios AA; Muñoz V; Hocquemiller R; Cavé A Trop Med Parasitol; 1992 Dec; 43(4):219-22. PubMed ID: 1293723 [TBL] [Abstract][Full Text] [Related]
17. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis. García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108 [TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Fournet A; Ferreira ME; Rojas De Arias A; Torres De Ortiz S; Fuentes S; Nakayama H; Schinini A; Hocquemiller R Antimicrob Agents Chemother; 1996 Nov; 40(11):2447-51. PubMed ID: 8913444 [TBL] [Abstract][Full Text] [Related]
19. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis. Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770 [TBL] [Abstract][Full Text] [Related]
20. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B. Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547 [No Abstract] [Full Text] [Related] [Next] [New Search]